DSDandan Song

Dandan Song

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Dandan Song has a total of 6 co-authors. Here are the top co-authors by number of shared publications:

  • Baoming Shen

    Department of Information Management the Affiliated Hospital of Qingdao University Qingdao China

    1 shared publication
  • Chengqian Li

    Department of Endocrine and Metabolic Diseases the Affiliated Hospital of Qingdao University Qingdao China

    1 shared publication
  • Wenjuan Zhao

    Department of Endocrine and Metabolic Diseases, The Affiliated Hospital of Qingdao University, Qingdao, China

    1 shared publication
  • Yuhang Zhao

    Department of Endocrine and Metabolic Diseases the Affiliated Hospital of Qingdao University Qingdao China

    1 shared publication
  • Zheng Ge

    Department of Hematology, Zhongda Hospital, School of Medicine, Southeast University, Institute of Hematology Southeast University, Nanjing, China

    1 shared publication
  • Zhongchao Wang

    Department of Endocrine and Metabolic Diseases the Affiliated Hospital of Qingdao University Qingdao China

    1 shared publication

Latest Publications

  • Open Access

    Azacitidine Combination with Lenalidomide in Treating Higher-Risk Myelodysplastic Syndromes: A Single-Center, Phase 2 Trial

    by Dandan Song, Zheng Ge

    Disclosures. No relevant conflicts of interest to declare.Figure 1

  • Open Access

    Association of non‐alcoholic fatty liver disease with diabetic retinopathy in type 2 diabetic patients: A meta‐analysis of observational studies

    by Dandan Song, Chengqian Li, Zhongchao Wang, Yuhang Zhao, Baoming Shen, Wenjuan Zhao

    Aims/Introduction: Non‐alcoholic fatty liver disease (NAFLD) is becoming more and more prevalent in type 2 diabetes mellitus. Evidence connecting NAFLD to diabetic retinopathy (DR) is increasing, but the results vary. Thus, we undertook a meta‐analysis to explore the effect of NAFLD on diabetic retinopathy in patients with type 2 diabetes mellitus.Materials and Methods: PubMed, Embase, Cochrane and Scopus database were searched for until September 30, 2019. Original studies analyzing the association between NAFLD and diabetic retinopathy in the type 2 diabetic population were included. This meta‐analysis was processed by RevMan 5.3 software. Subgroup analyses based on countries were carried out. The pooled odds ratios and 95% confidence intervals were used to evaluate the association between NAFLD and diabetic retinopathy incidence. The I2 test was used to assess heterogeneity of studies.Results: We retrieved 414 articles, and nine studies involving 7,170 patients were included in the final analysis. The pooled effects estimate suggested that NAFLD was not associated with the risk of diabetic retinopathy in patients with type 2 diabetes mellitus. Subgroup analysis suggested that in China, Korea and Iran, patients with type 2 diabetes mellitus with NAFLD had a decreased risk for diabetic retinopathy compared with the non‐NAFLD individuals. However, in Italy and India, patients with type 2 diabetes mellitus with NAFLD had an increased risk for diabetic retinopathy compared with the non‐NAFLD individuals. In addition, no relevance between NAFLD and diabetic retinopathy was found in America.Conclusions: On the whole, there was no association between NAFLD and diabetic retinopathy in individuals with type 2 diabetes mellitus. However, subgroup analysis showed that a difference of country may have an influence on the result.